Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.
about
Phage therapy of pulmonary infectionsEcology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm BacteriaBacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusModular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic FibrosisBacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex.Phage therapy--constraints and possibilities.The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-LactamsAerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.Identification of Essential Genes in the Salmonella Phage SPN3US Reveals Novel Insights into Giant Phage Head Structure and AssemblyThe search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.Next-Generation "-omics" Approaches Reveal a Massive Alteration of Host RNA Metabolism during Bacteriophage Infection of Pseudomonas aeruginosa.Phage fitness may help predict phage therapy efficacy.Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung.In Vivo Application of Bacteriophage as a Potential Therapeutic Agent To Control OXA-66-Like Carbapenemase-Producing Acinetobacter baumannii Strains Belonging to Sequence Type 357.Characterization and Comparative Genomic Analyses of Pseudomonas aeruginosa Phage PaoP5: New Members Assigned to PAK_P1-like VirusesNew perspectives in the management of Pseudomonas aeruginosa infections.Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages.Pseudomonas predators: understanding and exploiting phage-host interactions.Comparative transcriptomics analyses reveal the conservation of an ancestral infectious strategy in two bacteriophage genera.Commentary: Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro.Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections.Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa.Characterization and genomic study of "phiKMV-Like" phage PAXYB1 infecting Pseudomonas aeruginosa.Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions.Basic Phage Mathematics.Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models.Development and Validation of a Microtiter Plate-Based Assay for Determination of Bacteriophage Host Range and Virulence.Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.
P2860
Q26781119-5F8E2F55-9B0C-4709-9255-FDA3CBCF4EBEQ26786947-293F79FF-4879-4028-9BCB-20C8BFBF2EBFQ26799417-645B16D3-115D-44C0-A308-B29243264310Q28076246-566D99A7-E0C5-45F1-8D60-5AB2945D27C6Q30390256-D1A91AEC-4CD1-4E5C-A20C-405262FF706CQ33667556-0FBF4BED-DECA-4EE0-87A5-E87554A96AE7Q33696025-FBC74B33-520C-49E4-A106-2F0258F479CAQ33798541-D2B55677-6AFF-4DCE-9BD4-49FC0A90B03AQ34047363-74B8EB50-B6BA-4F9C-AA7A-CE3B5E84EB96Q35023371-36CAB977-6676-4A8C-94B2-9B932EDF7B86Q36068358-1607523A-74CE-4ACC-85C5-22225E358314Q36110277-2AD4ABC4-840E-4D66-B6C5-0384A5444FDAQ36571855-5BE9170E-4351-49D4-BF26-F7DD2E90E6F6Q37122285-4DAFCF5B-C581-4611-97B7-65E26F0B7BAEQ37278146-3E3E18F2-ECED-4BBF-8131-1CCAAB38D84BQ38243221-14F84449-A88F-443B-8B92-27D00E78A68CQ38989510-AB26DE3B-2245-4A38-B656-D565FF3D6380Q39083103-91F2873A-948C-422B-8724-F42C0ACEC794Q39397651-A8775B1E-2AEA-4888-A8B9-CC95F95FE59FQ40204030-E150721B-0A6A-4C4C-88C9-9FC287B348E2Q40604790-EB7FC7E7-E47A-4B51-8A5C-4D66FF750F7DQ41484363-7B462ED6-CAC5-479C-BEA7-CF9EE447EA5DQ42335330-639B7C95-965C-40B7-AFCC-5AAE25F29E31Q42376099-A0F3489E-1F8F-4D1C-9A34-21360D10301BQ47150323-D3F2BDB6-577F-4786-952F-DA602E71102EQ47610097-53500AC6-BA15-4BFA-B05C-E9D8E0CBCD54Q52648083-E4709AB2-D882-47C0-A3B4-3ECAA6ABDF83Q53696084-A6FD23AE-4F51-480B-ADDA-E41A7E0FC1DFQ54205022-77E0C575-CABF-464F-BF59-B953ED8F18CE
P2860
Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@en
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@nl
type
label
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@en
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@nl
prefLabel
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@en
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@nl
P2860
P356
P1476
Predicting in vivo efficacy of ...... to treat pulmonary infections.
@en
P2093
Marine Henry
P2860
P304
P356
10.1128/AAC.01596-13
P407
P577
2013-09-16T00:00:00Z